Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

zentiva, k.s. - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 25 mg - sitagliptiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 100 mg - sitagliptiini